PMID- 30655276
OWN - NLM
STAT- In-Data-Review
LR  - 20190118
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Jan 17
TI  - Delivering diabetes targets: five minutes with . . . Sam Everington.
PG  - l229
LID - 10.1136/bmj.l229 [doi]
FAU - Mayor, Susan
AU  - Mayor S
AD  - London, UK.
LA  - eng
PT  - Journal Article
DEP - 20190117
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2019/01/19 06:00
MHDA- 2019/01/19 06:00
CRDT- 2019/01/19 06:00
PHST- 2019/01/19 06:00 [entrez]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2019/01/19 06:00 [medline]
AID - 10.1136/bmj.l229 [doi]
PST - epublish
SO  - BMJ. 2019 Jan 17;364:l229. doi: 10.1136/bmj.l229.

PMID- 30651292
OWN - NLM
STAT- In-Data-Review
LR  - 20190117
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Jan 16
TI  - Nurses, shift work, and diabetes: should late chronotype be considered as a risk 
      factor?
PG  - l178
LID - 10.1136/bmj.l178 [doi]
FAU - Manfredini, Roberto
AU  - Manfredini R
AD  - Faculty of Medicine, Pharmacy and Prevention, University of Ferrara, via Fossato 
      di Mortara 46, 44121 Ferrara, Italy.
FAU - Cappadona, Rosaria
AU  - Cappadona R
AD  - Faculty of Medicine, Pharmacy and Prevention, University of Ferrara, via Fossato 
      di Mortara 46, 44121 Ferrara, Italy.
FAU - Fabbian, Fabio
AU  - Fabbian F
AD  - Faculty of Medicine, Pharmacy and Prevention, University of Ferrara, via Fossato 
      di Mortara 46, 44121 Ferrara, Italy.
LA  - eng
PT  - Letter
DEP - 20190116
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
COIS- Competing interests: None declared.
EDAT- 2019/01/18 06:00
MHDA- 2019/01/18 06:00
CRDT- 2019/01/18 06:00
PHST- 2019/01/18 06:00 [entrez]
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2019/01/18 06:00 [medline]
AID - 10.1136/bmj.l178 [doi]
PST - epublish
SO  - BMJ. 2019 Jan 16;364:l178. doi: 10.1136/bmj.l178.

PMID- 30651233
OWN - NLM
STAT- In-Data-Review
LR  - 20190117
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Jan 16
TI  - Shift work and diabetes: alcohol consumption as a risk factor.
PG  - l177
LID - 10.1136/bmj.l177 [doi]
FAU - Skovenborg, Erik
AU  - Skovenborg E
AD  - 8000 Aarhus, Denmark.
LA  - eng
PT  - Letter
DEP - 20190116
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
COIS- Competing interests: None declared.
EDAT- 2019/01/18 06:00
MHDA- 2019/01/18 06:00
CRDT- 2019/01/18 06:00
PHST- 2019/01/18 06:00 [entrez]
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2019/01/18 06:00 [medline]
AID - 10.1136/bmj.l177 [doi]
PST - epublish
SO  - BMJ. 2019 Jan 16;364:l177. doi: 10.1136/bmj.l177.

PMID- 30677187
OWN - NLM
STAT- Publisher
LR  - 20190212
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 24
TI  - Impact of physical exercise on sensor performance of the FreeStyle Libre
      intermittently viewed continuous glucose monitoring system in people with Type 1 
      diabetes: a randomized crossover trial.
LID - 10.1111/dme.13909 [doi]
AB  - AIMS: To evaluate the sensor performance of the FreeStyle Libre intermittently
      viewed continuous glucose monitoring system using reference blood glucose levels 
      during moderate-intensity exercise while on either full or reduced basal insulin 
      dose in people with Type 1 diabetes. METHODS: Ten participants with Type 1
      diabetes [four women, mean +/- sd age 31.4 +/- 9.0 years, BMI 25.5+/-3.8 kg/m(2) 
      , HbA1c 55+/-7 mmol/mol (7.2+/-0.6%)] exercised on a cycle ergometer for 55 min
      at a moderate intensity for 5 consecutive days at the clinical research facility,
      while receiving either their usual or a 75% basal insulin dose. After a 4-week
      washout period, participants performed the second exercise period having switched
      to the alternative basal insulin dose. During exercise, reference capillary blood
      glucose values were analysed using the fully enzymatic-amperometric method and
      compared with the interstitial glucose values obtained. Intermittently viewed
      continuous glucose monitoring accuracy was analysed according to median
      (interquartile range) absolute relative difference, and Clarke error grid and
      Bland-Altman analysis for overall glucose levels during exercise, stratified by
      glycaemic range and basal insulin dosing scheme (P<0.05). RESULTS: A total of 845
      glucose values were available during exercise to evaluate intermittently viewed
      continuous glucose monitoring sensor performance. The median (interquartile
      range) absolute relative difference between the reference values and those
      obtained by the sensor across the glycaemic range overall was 22 (13.9-29.7)%,
      and was 36.3 (24.2-45.2)% during hypoglycaemia, 22.8 (14.6-30.6)% during
      euglycaemia and 15.4 (9-21)% during hyperglycaemia. Usual basal insulin dose was 
      associated with a worse sensor performance during exercise compared with the
      reduced (75%) basal insulin dose [median (interquartile range) absolute relative 
      difference: 23.7 (17.2-30.7)% vs 20.5 (12-28.1)%; P<0.001). CONCLUSIONS: The
      intermittently viewed continuous glucose monitoring sensor showed diminished
      accuracy during exercise. Absolute glucose readings derived from the sensor
      should be used cautiously and need confirmation by additional finger-prick blood 
      glucose measurements.
CI  - (c) 2019 Diabetes UK.
FAU - Moser, O
AU  - Moser O
AD  - Diabetes Research Group, Medical School, Swansea University, Swansea, UK.
AD  - Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM),
      College of Engineering, Swansea University, Swansea, UK.
FAU - Eckstein, M L
AU  - Eckstein ML
AD  - Diabetes Research Group, Medical School, Swansea University, Swansea, UK.
AD  - Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM),
      College of Engineering, Swansea University, Swansea, UK.
FAU - Mueller, A
AU  - Mueller A
AD  - Exercise Physiology, Training and Training Therapy Research Group, Institute of
      Sports Science, Medical University of Graz, Graz, Austria.
AD  - Sport Science Laboratory, FH Joanneum University of Applied Science, Bad
      Gleichenberg, Austria.
FAU - Birnbaumer, P
AU  - Birnbaumer P
AD  - Exercise Physiology, Training and Training Therapy Research Group, Institute of
      Sports Science, Medical University of Graz, Graz, Austria.
FAU - Aberer, F
AU  - Aberer F
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Graz, Austria.
FAU - Koehler, G
AU  - Koehler G
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Graz, Austria.
FAU - Sourij, C
AU  - Sourij C
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Graz, Austria.
FAU - Kojzar, H
AU  - Kojzar H
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Graz, Austria.
FAU - Holler, P
AU  - Holler P
AD  - Sport Science Laboratory, FH Joanneum University of Applied Science, Bad
      Gleichenberg, Austria.
FAU - Simi, H
AU  - Simi H
AD  - Sport Science Laboratory, FH Joanneum University of Applied Science, Bad
      Gleichenberg, Austria.
FAU - Pferschy, P
AU  - Pferschy P
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Graz, Austria.
FAU - Dietz, P
AU  - Dietz P
AD  - Department of Physical Activity and Public Health, Institute of Sports Science,
      Medical University of Graz, Graz, Austria.
AD  - Institute of Occupational, Social and Environmental Medicine, University Medical 
      Centre of the University of Mainz, Mainz, Germany.
FAU - Bracken, R M
AU  - Bracken RM
AD  - Diabetes Research Group, Medical School, Swansea University, Swansea, UK.
AD  - Applied Sport, Technology, Exercise and Medicine Research Centre (A-STEM),
      College of Engineering, Swansea University, Swansea, UK.
FAU - Hofmann, P
AU  - Hofmann P
AD  - Exercise Physiology, Training and Training Therapy Research Group, Institute of
      Sports Science, Medical University of Graz, Graz, Austria.
FAU - Sourij, H
AU  - Sourij H
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine,
      Medical University of Graz, Graz, Austria.
LA  - eng
GR  - Novo Nordisk, Austria
PT  - Journal Article
DEP - 20190124
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/25 06:00
MHDA- 2019/01/25 06:00
CRDT- 2019/01/25 06:00
PHST- 2018/12/05 00:00 [accepted]
PHST- 2019/01/25 06:00 [pubmed]
PHST- 2019/01/25 06:00 [medline]
PHST- 2019/01/25 06:00 [entrez]
AID - 10.1111/dme.13909 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 24. doi: 10.1111/dme.13909.

PMID- 30677175
OWN - NLM
STAT- Publisher
LR  - 20190215
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 24
TI  - Theory-based diabetes self-management education with pre-selection of
      participants: a randomized controlled trial with 2.5 years' follow-up (ELDES
      Study).
LID - 10.1111/dme.13907 [doi]
AB  - AIMS: To evaluate the (cost-)effectiveness of Beyond Good Intentions (BGI), a
      12-week group-based, nurse-led self-management programme, in terms of
      cardiovascular risk factors, self-management and quality of life, after 2.5 years
      of follow-up in pre-selected individuals with known Type 2 diabetes of up to 5
      years' duration. METHODS: A parallel randomized controlled trial comparing BGI
      with usual care, based on a self-management screening questionnaire, was
      conducted in 43 general practices after pre-selection of participants. After 2.5 
      years of follow-up, the between-group changes in the abovementioned variables
      were assessed using analysis of covariance. RESULTS: A total of 108 participants 
      (BGI group, n =56; control group, n =52) were included. Changes over time in BMI 
      (-0.4 vs -0.5 kg/m(2) ) were similar in the two groups. Median HbA1c [BGI group
      47 mmol/mol (6.5%); control group: 49 mmol/mol (6.6%)] and mean systolic blood
      pressure (BGI group: 132+/-13 mmHg; control group: 133+/-14 mmHg) were well
      controlled at baseline and no intervention effect was found. LDL cholesterol
      levels decreased from 2.4 to 2.2 mmol/l in the control group and remained stable 
      at 2.6 mmol/l in the intervention group (P=0.032). No intervention effect was
      found for self-management or quality of life. CONCLUSION: In contrast to the
      first BGI study, we did not observe significant effects of the BGI intervention, 
      despite pre-selection of individuals. In diabetes populations with target levels 
      for HbA1c , systolic blood pressure and LDL cholesterol, no further beneficial
      effects can be expected from self-management programmes with regard to biomedical
      factors and quality of life.
CI  - (c) 2019 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on
      behalf of Diabetes UK.
FAU - Vos, R C
AU  - Vos RC
AUID- ORCID: https://orcid.org/0000-0003-1074-6255
AD  - Julius Centre for Health Sciences and Primary Care, Department of General
      Practice, University Medical Centre Utrecht, Utrecht University, Utrecht.
AD  - Leiden University Medical Centre, Department of Public Health and Primary
      Care/LUMC-Campus The Hague, Eindhoven, The Netherlands.
FAU - van Heusden, L
AU  - van Heusden L
AD  - Julius Centre for Health Sciences and Primary Care, Department of General
      Practice, University Medical Centre Utrecht, Utrecht University, Utrecht.
FAU - Eikelenboom, N W D
AU  - Eikelenboom NWD
AD  - DOH Care Group, Eindhoven, The Netherlands.
FAU - Rutten, G E H M
AU  - Rutten GEHM
AD  - Julius Centre for Health Sciences and Primary Care, Department of General
      Practice, University Medical Centre Utrecht, Utrecht University, Utrecht.
LA  - eng
GR  - EFSD / AZ-BMS Grant 2013/European Foundation for the Study of Diabetes (EFSD)
PT  - Journal Article
DEP - 20190124
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/25 06:00
MHDA- 2019/01/25 06:00
CRDT- 2019/01/25 06:00
PHST- 2019/01/22 00:00 [accepted]
PHST- 2019/01/25 06:00 [pubmed]
PHST- 2019/01/25 06:00 [medline]
PHST- 2019/01/25 06:00 [entrez]
AID - 10.1111/dme.13907 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 24. doi: 10.1111/dme.13907.

PMID- 30677170
OWN - NLM
STAT- Publisher
LR  - 20190124
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 24
TI  - Incidence of sight-threatening diabetic retinopathy in people with Type 2
      diabetes mellitus and numbers needed to screen: a systematic review.
LID - 10.1111/dme.13908 [doi]
AB  - AIM: To investigate the incidence of sight-threatening diabetic retinopathy in
      Type 2 diabetes mellitus. BACKGROUND: In most countries, yearly or biennial
      screening intervals for diabetic retinopathy in people with Type 2 diabetes are
      recommended. Fewer screening sessions reduce the effort required of people with
      Type 2 diabetes and reduce healthcare costs. METHODS: We conducted a search of
      PubMed, Embase, Web of Science and the COCHRANE Library for studies published
      betweeen 1 January 2000 and 1 January 2017. Eligible studies were those that
      included general populations of >100 people with Type 2 diabetes mellitus.
      Additional study population criteria were absence of moderate diabetic
      retinopathy or more severe diabetic retinopathy than previously at last screening
      session and at least two successful retinal screening sessions. Outcomes of
      interest in the included studies were moderate and severe non-proliferative
      diabetic retinopathy (R2), proliferative diabetic retinopathy (R3) or maculopathy
      (M1), collectively known as sight-threatening or referable diabetic retinopathy. 
      RESULTS: A total of 17 studies were included. In people with Type 2 diabetes
      without or with only mild diabetic retinopathy at baseline, the average incidence
      rates of sight-threatening diabetic retinopathy were ~1 per 100 person-years and 
      ~8 per 100 person-years, respectively. The average numbers needed to screen to
      detect one case of sight-threatening diabetic retinopathy were 175 and 19 in
      people without and with mild retinopathy at last screening, respectively.
      CONCLUSION: In people with Type 2 diabetes without retinopathy at last screening,
      the incidence of severe sight-threatening retinopathy at the subsequent screening
      session was low. In people with mild retinopathy, progression to
      sight-threatening diabetic retinopathy was nearly 10-fold higher. This review
      supports lengthening of the screening interval of patients with Type 2 diabetes
      without retinopathy at last screening session. This article is protected by
      copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Groeneveld, Y
AU  - Groeneveld Y
AD  - Department of Public Health and Primary Care, Leiden University Medical Centre,
      Leiden.
FAU - Tavenier, D
AU  - Tavenier D
AD  - Group Practice Asklepion, Barneveld, VU University Medical Centre, Amsterdam, The
      Netherlands.
FAU - Blom, J W
AU  - Blom JW
AD  - Department of Public Health and Primary Care, Leiden University Medical Centre,
      Leiden.
FAU - Polak, B C P
AU  - Polak BCP
AD  - Department of Ophthalmology, EMGO Institute for Health and Care Research, VU
      University Medical Centre, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20190124
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/25 06:00
MHDA- 2019/01/25 06:00
CRDT- 2019/01/25 06:00
PHST- 2019/01/25 06:00 [entrez]
PHST- 2019/01/25 06:00 [pubmed]
PHST- 2019/01/25 06:00 [medline]
AID - 10.1111/dme.13908 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 24. doi: 10.1111/dme.13908.

PMID- 30672019
OWN - NLM
STAT- Publisher
LR  - 20190123
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 22
TI  - Clinical utility of ultrasonography-measured visceral adipose tissue depth as a
      tool in early pregnancy screening for gestational diabetes: a proof-of-concept
      study.
LID - 10.1111/dme.13906 [doi]
AB  - AIM: To examine, in a proof-of-concept study, the ability of visceral adipose
      tissue depth and subcutaneous fat depth measured in early pregnancy to predict
      subsequent gestational diabetes, and to assess the performance of these measures 
      as screening tests for gestational diabetes compared with use of the current UK
      criteria. METHODS: A total of 100 women in early pregnancy were recruited from a 
      maternity hospital in Belfast, UK. Visceral adipose tissue depth and subcutaneous
      fat depth were measured, and each participant underwent a 75-g oral glucose
      tolerance test at 28 weeks' gestation for the diagnosis of gestational diabetes
      using WHO 2013 criteria. RESULTS: Eighty women completed the study, of whom 15
      (19%) developed gestational diabetes. Increasing visceral adipose tissue depth,
      but not subcutaneous fat depth, was associated with greater gestational diabetes 
      risk after adjusting for confounding factors (odds ratio for a 1-sd rise 2.09,
      95% CI 1.06-4.12; P=0.03). Visceral adipose tissue depth >/=4.27 cm had greater
      sensitivity compared with current National Institute of Health and Care
      Excellence criteria (87% vs 40%, respectively; P=0.02) and similar specificity
      (62% vs 74%, respectively; P=0.15) for identifying gestational diabetes.
      CONCLUSIONS: Ultrasonography-measured visceral adipose tissue in early pregnancy 
      is a potential clinical tool for improving sensitivity of selective screening for
      gestational diabetes, which, compared with universal oral glucose tolerance
      testing, is likely to reduce by half the numbers requiring this test. Further
      larger studies are now required for confirmation, including investigation into
      impact on clinical outcomes. This article is protected by copyright. All rights
      reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Thaware, P K
AU  - Thaware PK
AD  - Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast,
      UK.
FAU - Patterson, C C
AU  - Patterson CC
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Young, I S
AU  - Young IS
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - Casey, C
AU  - Casey C
AD  - Centre for Public Health, Queen's University Belfast, Belfast, UK.
FAU - McCance, D R
AU  - McCance DR
AD  - Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20190122
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/24 06:00
MHDA- 2019/01/24 06:00
CRDT- 2019/01/24 06:00
PHST- 2019/01/24 06:00 [entrez]
PHST- 2019/01/24 06:00 [pubmed]
PHST- 2019/01/24 06:00 [medline]
AID - 10.1111/dme.13906 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 22. doi: 10.1111/dme.13906.

PMID- 30672017
OWN - NLM
STAT- Publisher
LR  - 20190216
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 22
TI  - Assessing the severity of Type 2 diabetes using clinical data-based measures: a
      systematic review.
LID - 10.1111/dme.13905 [doi]
AB  - AIMS: To identify and critically appraise measures that use clinical data to
      grade the severity of Type 2 diabetes. METHODS: We searched MEDLINE, Embase and
      PubMed between inception and June 2018. Studies reporting on clinical data-based 
      diabetes-specific severity measures in adults with Type 2 diabetes were included.
      We excluded studies conducted solely in participants with other types of
      diabetes. After independent screening, the characteristics of the eligible
      measures including design and severity domains, the clinical utility of developed
      measures, and the relationship between severity levels and health-related
      outcomes were assessed. RESULTS: We identified 6798 studies, of which 17 studies 
      reporting 18 different severity measures (32 314 participants in 17 countries)
      were included: a diabetes severity index (eight studies, 44%); severity
      categories (seven studies, 39%); complication count (two studies, 11%); and a
      severity checklist (one study, 6%). Nearly 89% of the measures included
      diabetes-related complications and/or glycaemic control indicators. Two of the
      severity measures were validated in a separate study population. More severe
      diabetes was associated with increased healthcare costs, poorer cognitive
      function and significantly greater risks of hospitalization and mortality. The
      identified measures differed greatly in terms of the included domains. One study 
      reported on the use of a severity measure prospectively. CONCLUSIONS: Health
      records are suitable for assessment of diabetes severity; however, the clinical
      uptake of existing measures is limited. The need to advance this research area is
      fundamental as higher levels of diabetes severity are associated with greater
      risks of adverse outcomes. Diabetes severity assessment could help identify
      people requiring targeted and intensive therapies and provide a major benchmark
      for efficient healthcare services.
CI  - (c) 2019 Diabetes UK.
FAU - Zghebi, S S
AU  - Zghebi SS
AUID- ORCID: https://orcid.org/0000-0002-7978-1094
AD  - Division of Population Health, Health Services Research and Primary Care, School 
      of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic 
      Health Science Centre (MAHSC), University of Manchester, Manchester.
AD  - NIHR School for Primary Care Research, Centre for Primary Care, Manchester
      Academic Health Science Centre (MAHSC), University of Manchester, Manchester.
FAU - Panagioti, M
AU  - Panagioti M
AD  - Division of Population Health, Health Services Research and Primary Care, School 
      of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic 
      Health Science Centre (MAHSC), University of Manchester, Manchester.
AD  - NIHR School for Primary Care Research, Centre for Primary Care, Manchester
      Academic Health Science Centre (MAHSC), University of Manchester, Manchester.
FAU - Rutter, M K
AU  - Rutter MK
AD  - Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology,
      Medicine and Health, Manchester Academic Health Science Centre (MAHSC),
      University of Manchester, Manchester.
AD  - Manchester Diabetes Centre, Manchester University NHS Foundation Trust,
      Manchester Academic Health Science Centre (MAHSC), Manchester, Manchester.
FAU - Ashcroft, D M
AU  - Ashcroft DM
AD  - NIHR School for Primary Care Research, Centre for Primary Care, Manchester
      Academic Health Science Centre (MAHSC), University of Manchester, Manchester.
AD  - Centre for Pharmacoepidemiology and Drug Safety, School of Health Sciences,
      Faculty of Biology, Medicine and Health, Manchester Academic Health Science
      Centre (MAHSC), University of Manchester, Manchester.
FAU - van Marwijk, H
AU  - van Marwijk H
AD  - Division of Primary Care and Public Health, Brighton and Sussex Medical School,
      University of Brighton, Brighton.
FAU - Salisbury, C
AU  - Salisbury C
AD  - Centre for Academic Primary Care, Department of Population Health Sciences,
      Bristol Medical School, Bristol.
FAU - Chew-Graham, C A
AU  - Chew-Graham CA
AD  - Research Institute for Primary Care and Health Sciences, Keele University,
      Staffordshire.
FAU - Buchan, I
AU  - Buchan I
AD  - Division of Population Health, Health Services Research and Primary Care, School 
      of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic 
      Health Science Centre (MAHSC), University of Manchester, Manchester.
AD  - Health eResearch Centre, Division of Informatics, Imaging and Data Science,
      School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester
      Academic Health Science Centre, University of Manchester, Manchester.
AD  - Department of Public Health and Policy, Institute of Population Health Sciences, 
      University of Liverpool, Liverpool.
FAU - Qureshi, N
AU  - Qureshi N
AD  - Primary Care Stratified Medicine (PriSM) group, Division of Primary Care, School 
      of Medicine, University of Nottingham, Nottingham.
FAU - Peek, N
AU  - Peek N
AD  - Health eResearch Centre, Division of Informatics, Imaging and Data Science,
      School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester
      Academic Health Science Centre, University of Manchester, Manchester.
FAU - Mallen, C
AU  - Mallen C
AD  - Research Institute for Primary Care and Health Sciences, Keele University,
      Staffordshire.
FAU - Mamas, M
AU  - Mamas M
AD  - Keele Cardiovascular Research group, Centre for Prognosis Research, Institute for
      Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK.
FAU - Kontopantelis, E
AU  - Kontopantelis E
AUID- ORCID: https://orcid.org/0000-0001-6450-5815
AD  - Division of Population Health, Health Services Research and Primary Care, School 
      of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic 
      Health Science Centre (MAHSC), University of Manchester, Manchester.
AD  - NIHR School for Primary Care Research, Centre for Primary Care, Manchester
      Academic Health Science Centre (MAHSC), University of Manchester, Manchester.
LA  - eng
GR  - 331/National Institute of Health Research (NIHR) School for Primary Care Research
      (SPCR)
PT  - Journal Article
PT  - Review
DEP - 20190122
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/24 06:00
MHDA- 2019/01/24 06:00
CRDT- 2019/01/24 06:00
PHST- 2019/01/21 00:00 [accepted]
PHST- 2019/01/24 06:00 [pubmed]
PHST- 2019/01/24 06:00 [medline]
PHST- 2019/01/24 06:00 [entrez]
AID - 10.1111/dme.13905 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 22. doi: 10.1111/dme.13905.

PMID- 30663133
OWN - NLM
STAT- Publisher
LR  - 20190212
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 21
TI  - A comparison between point-of-care testing and venous glucose determination for
      the diagnosis of diabetes mellitus 6-12 weeks after gestational diabetes.
LID - 10.1111/dme.13903 [doi]
AB  - AIM: To evaluate point-of-care-testing (POCT) for the diagnosis of Type 2
      diabetes mellitus 6-12 weeks post-partum in women with gestational diabetes
      (GDM). METHODS: Post-partum glucose assessment (75-mg oral glucose tolerance
      test, OGTT) was performed prospectively in 122 women with GDM (1 November 2015 to
      1 November 2017) at Tygerberg Hospital, Cape Town, South Africa. Individuals with
      known pre-existing diabetes were excluded. The accuracy and clinical utility of
      POCT (capillary finger-prick) were compared with laboratory plasma glucose
      (hexokinase and glucokinase methods). The OGTT consisted of two time points
      (fasting and 2 h) during which concurrent glucose samples (POCT and laboratory)
      were obtained. Bland-Altman plots and paired analysis were used to assess the
      analytical accuracy of POCT, whereas its diagnostic performance was determined
      using positive and negative predictive values to calculate specificity and
      sensitivity. RESULTS: Spearman's ranked correlation analysis indicated a strong
      association between POCT and laboratory glucose values at both OGTT time points
      (fasting, r = 0.95, P < 0.0001; 2 h, r = 0.88, P < 0.0001). Thirty-six women were
      diagnosed with Type 2 diabetes based on gold standard laboratory glucose levels
      (fasting > 7 mmol/l; 2 h > 11.1 mmol/l). POCT correctly identified Type 2
      diabetes in 78% of women (28 of 36) with a positive predictive value of 89.3% and
      a negative predictive value of 96.7% at the fasting time point. The sensitivity
      and specificity of POCT to diagnose Type 2 diabetes were 89% (fasting), 85.7% (2 
      h) and 96.7% (fasting), 98.5% (2 h) respectively. POCT proved less sensitive to
      diagnose pre-diabetes (69%) but displayed satisfactory specificity (92%) at both 
      time points assessed. CONCLUSION: POCT accurately identifies women with Type 2
      diabetes 6-12 weeks after GDM.
CI  - (c) 2019 Diabetes UK.
FAU - Coetzee, A
AU  - Coetzee A
AUID- ORCID: https://orcid.org/0000-0001-9993-6439
AD  - Department of Medicine, Stellenbosch University, Cape Town, South Africa.
AD  - Tygerberg Academic Hospital, Cape Town, South Africa.
FAU - van de Vyver, M
AU  - van de Vyver M
AD  - Department of Medicine, Stellenbosch University, Cape Town, South Africa.
FAU - Hoffmann, M
AU  - Hoffmann M
AD  - Department of Pathology, Stellenbosch University and the National Health
      Laboratory Service, Cape Town, South Africa.
FAU - Hall, D R
AU  - Hall DR
AD  - Tygerberg Academic Hospital, Cape Town, South Africa.
AD  - Department of Obstetrics and Gynaecology, Stellenbosch University, Cape Town,
      South Africa.
FAU - Mason, D
AU  - Mason D
AD  - Tygerberg Academic Hospital, Cape Town, South Africa.
AD  - Department of Obstetrics and Gynaecology, Stellenbosch University, Cape Town,
      South Africa.
FAU - Conradie, M
AU  - Conradie M
AD  - Department of Medicine, Stellenbosch University, Cape Town, South Africa.
AD  - Tygerberg Academic Hospital, Cape Town, South Africa.
LA  - eng
PT  - Journal Article
DEP - 20190121
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/22 06:00
MHDA- 2019/01/22 06:00
CRDT- 2019/01/22 06:00
PHST- 2019/01/17 00:00 [accepted]
PHST- 2019/01/22 06:00 [pubmed]
PHST- 2019/01/22 06:00 [medline]
PHST- 2019/01/22 06:00 [entrez]
AID - 10.1111/dme.13903 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 21. doi: 10.1111/dme.13903.

PMID- 30663119
OWN - NLM
STAT- Publisher
LR  - 20190121
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 21
TI  - The challenge of managing Type 1 diabetes in frail older people.
LID - 10.1111/dme.13904 [doi]
AB  - The incidence of Type 1 diabetes is increasing by 2-5% per year and is consistent
      throughout the first six decades of life [1], with greater numbers reaching older
      age [2]. Although autonomy to manage Type 1 diabetes is encouraged, problems
      arise when an individual is less able to make day-to-day decisions regarding
      their diabetes. Ability to self-manage cannot be readily passed onto family
      members, and older adults with Type 1 diabetes are increasingly reliant on care
      from the community. Recurrent admissions occur when older adults forget to take
      insulin despite input from district nurses, and there can be difficulties
      surrounding choice of insulin regimen when nutritional intake is poor. This
      article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
FAU - Brooks, A
AU  - Brooks A
AD  - Bournemouth Diabetes& Endocrine Centre, Royal Bournemouth Hospital, Bournemouth, 
      Brighton, UK.
FAU - Chakera, A J
AU  - Chakera AJ
AD  - Royal Sussex County Hospital, Brighton and Sussex University Hospitals, Brighton,
      UK.
LA  - eng
PT  - Journal Article
DEP - 20190121
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/22 06:00
MHDA- 2019/01/22 06:00
CRDT- 2019/01/22 06:00
PHST- 2019/01/22 06:00 [entrez]
PHST- 2019/01/22 06:00 [pubmed]
PHST- 2019/01/22 06:00 [medline]
AID - 10.1111/dme.13904 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 21. doi: 10.1111/dme.13904.

PMID- 30659656
OWN - NLM
STAT- Publisher
LR  - 20190213
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 19
TI  - Projected number of people with diagnosed Type 2 diabetes in Germany in 2040.
LID - 10.1111/dme.13902 [doi]
AB  - AIMS: To project the number of people with Type 2 diabetes in Germany between
      2015 and 2040. METHODS: Based on data from 65 million insurees of the German
      statutory health insurance, we projected the age-specific prevalence of diabetes 
      using mathematical relations between prevalence, incidence rate and mortality. We
      compared several scenarios regarding temporal trends in the incidence and
      mortality rate. The projected age-specific prevalence was applied to the
      projected age structure of the German population between 2015 and 2040 to
      calculate the number of people with Type 2 diabetes. RESULTS: Application of
      current age-specific prevalence estimates to the projected age structure in 2040,
      although ignoring temporal trends in incidence and mortality, yielded an increase
      in the number of Type 2 diabetes cases from 6.9 million in 2015 to 8.3 million
      (+21%) in 2040. More realistic scenarios that account for decreasing mortality
      rates and different trends in the incidence rates project between 10.7 million
      (+54%) and 12.3 million (+77%) Type 2 diabetes cases in 2040. CONCLUSIONS: For
      the first time, we projected the number of future Type 2 diabetes cases for the
      whole adult population in Germany. The results indicate a relative increase in
      the number of Type 2 diabetes cases of between 54% and 77% from 2015 to 2040.
      Temporal trends in the incidence rate are the main drivers of this increase.
      Simply applying current age-specific prevalence to the future age structure
      probably underestimates the future number of Type 2 diabetes cases.
CI  - (c) 2019 Diabetes UK.
FAU - Tonnies, T
AU  - Tonnies T
AUID- ORCID: https://orcid.org/0000-0003-1577-4212
AD  - Institute for Biometrics and Epidemiology, German Diabetes Center (DDZ), Leibniz 
      Center for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
FAU - Rockl, S
AU  - Rockl S
AD  - Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, 
      Germany.
FAU - Hoyer, A
AU  - Hoyer A
AUID- ORCID: https://orcid.org/0000-0002-0241-9951
AD  - Institute for Biometrics and Epidemiology, German Diabetes Center (DDZ), Leibniz 
      Center for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
FAU - Heidemann, C
AU  - Heidemann C
AD  - Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, 
      Germany.
FAU - Baumert, J
AU  - Baumert J
AUID- ORCID: https://orcid.org/0000-0003-1399-6874
AD  - Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, 
      Germany.
FAU - Du, Y
AU  - Du Y
AUID- ORCID: https://orcid.org/0000-0001-8309-9293
AD  - Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, 
      Germany.
FAU - Scheidt-Nave, C
AU  - Scheidt-Nave C
AD  - Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, 
      Germany.
FAU - Brinks, R
AU  - Brinks R
AD  - Institute for Biometrics and Epidemiology, German Diabetes Center (DDZ), Leibniz 
      Center for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
AD  - Hiller Research Unit for Rheumatology, University Hospital Duesseldorf,
      Dusseldorf, Germany.
LA  - eng
GR  - FKZ: GE20160324/German Federal Ministry of Health
PT  - Journal Article
DEP - 20190119
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/20 06:00
MHDA- 2019/01/20 06:00
CRDT- 2019/01/20 06:00
PHST- 2019/01/16 00:00 [accepted]
PHST- 2019/01/20 06:00 [pubmed]
PHST- 2019/01/20 06:00 [medline]
PHST- 2019/01/20 06:00 [entrez]
AID - 10.1111/dme.13902 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 19. doi: 10.1111/dme.13902.

PMID- 30659650
OWN - NLM
STAT- Publisher
LR  - 20190214
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 19
TI  - The 2017 Banting Memorial Lecture The diabetic lower limb - a forty year journey:
      from clinical observation to clinical science.
LID - 10.1111/dme.13901 [doi]
AB  - A series of clinical research projects conducted over the past 40 years, all of
      which were informed by clinical observation or discussions with people with
      diabetes and staff colleagues are described in this review. A study of
      necrobiosis lipoidica diabeticorum confirmed that this rare skin complication
      occurs predominantly in young women with Type 1 diabetes and other microvascular 
      complications. Biopsies of necrobiotic lesions showed destruction of superficial 
      nerve fibres by inflammatory tissue, which likely causes the sensory loss in
      lesions that is pathognomonic of the condition. The development of corneal
      confocal microscopy as a new non-invasive surrogate marker of peripheral
      neuropathy in diabetes is described next and several small studies of the use of 
      this new technique in clinical research are reported. The influence of blood
      glucose instability on the genesis of neuropathic pain is then explained, with
      results suggesting that the stability of glycaemic control may be more important 
      than the level of control achieved. Lastly, in neuropathy, studies of gustatory
      sweating are discussed, including the observation that sweating in the head and
      neck region is more common in people with end-stage diabetic nephropathy than in 
      those with neuropathy. The disappearance of gustatory sweating after renal
      transplantation suggests a metabolic cause and for those with troublesome
      sweating, use of the anticholinergic, anti-muscarinic, topical cream
      glycopyrrolate is confirmed in a randomized control trial. In the area of
      diabetic foot research, distended dorsal foot veins were observed to be a
      clinical sign of sympathetic autonomic neuropathy: raised venous Po2 and Doppler 
      abnormalities of blood flow are highly suggestive of arteriovenous shunting. A
      series of studies of the abnormalities of pressures and loads under the
      neuropathic diabetic foot are described: high dynamic plantar pressures are
      highly predictive of subsequent ulceration in the neuropathic foot. Lastly, a
      number of recent studies on unsteadiness and gait abnormalities when climbing and
      descending stairs are described. It is hoped that the art of clinical observation
      survives in the highly technological 21st century.
CI  - (c) 2019 Diabetes UK.
FAU - Boulton, Andrew J M
AU  - Boulton AJM
AD  - Division of Diabetes, Endocrinology and Gastroenterology, School of Medical
      Sciences, University of Manchester, Manchester, UK.
AD  - Manchester Royal Infirmary, Manchester, UK.
AD  - Diabetes Research Institute, University of Miami, Miami, FL, USA.
LA  - eng
GR  - National Institutes of Health/National Institutes of Diabetes, Digestive and
      Kidney Diseases Section
GR  - Wellcome Trust
GR  - Diabetes UK
GR  - European Foundation for the Study of Diabetes
PT  - Journal Article
PT  - Review
DEP - 20190119
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/20 06:00
MHDA- 2019/01/20 06:00
CRDT- 2019/01/20 06:00
PHST- 2019/01/16 00:00 [accepted]
PHST- 2019/01/20 06:00 [pubmed]
PHST- 2019/01/20 06:00 [medline]
PHST- 2019/01/20 06:00 [entrez]
AID - 10.1111/dme.13901 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 19. doi: 10.1111/dme.13901.

PMID- 30653705
OWN - NLM
STAT- Publisher
LR  - 20190221
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 17
TI  - Intensification patterns and the probability of HbA1c goal attainment in Type 2
      diabetes mellitus: real-world evidence for the concept of 'intensification
      inertia'.
LID - 10.1111/dme.13900 [doi]
AB  - AIMS: To assess the effects of 'clinical' and 'intensification inertia' by
      evaluating the impact of different intensification interventions on the
      probability of HbA1c goal attainment using real-world data. METHODS: Electronic
      health records (Cleveland Clinic, 2005-2016) were used to identify 7389 people
      with Type 2 diabetes mellitus and HbA1c >/=53 mmol/mol (>/=7.0%), despite a
      stable regimen of two oral antihyperglycaemic drugs for >/=6 months. The
      participants were stratified by index HbA1c and analysed over a 6-month period
      for pharmacological intensification, and then for 12 additional months for HbA1c 
      goal attainment (<53 mmol/mol). RESULTS: The probability of HbA1c goal attainment
      (Kaplan-Meier analysis) in the group with index HbA1c 53-63 mmol/mol (7.0-7.9%)
      was highest with the addition of oral antidiabetic drugs [57.3% (95% CI 52.1,
      62.0)] or glucagon-like peptide-1 receptor agonists [56.7% (95% CI 40.4, 68.6)], 
      in the 64-74 mmol/mol (8.0-8.9%) group with the addition of oral antidiabetic
      drugs [31.9% (95% CI 25.1, 38.1)] or insulin [30.6% (95% CI 18.3, 41.0)], and in 
      the >/=75 mmol/mol (>/=9.0%) group with the addition of glucagon-like peptide-1
      receptor agonists [53.0% (95% CI 31.8, 67.6)] or insulin [43.5% (95% CI 36.4,
      49.8)]. CONCLUSIONS: Numerical, but not statistically significant, differences in
      HbA1c goal attainment probability by type of intensification were most marked in 
      people with the highest index HbA1c [>/=75 mmol/mol (>/=9.0%)]; in this group,
      injectable therapy showed trends toward greater glycaemic control benefits.
      Additional research into the phenomenon of intensification inertia is warranted.
CI  - (c) 2019 Diabetes UK.
FAU - Pantalone, K M
AU  - Pantalone KM
AUID- ORCID: http://orcid.org/0000-0002-3897-4551
AD  - Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Misra-Hebert, A D
AU  - Misra-Hebert AD
AD  - Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
AD  - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
FAU - Hobbs, T M
AU  - Hobbs TM
AD  - Chief Medical Officer, Novo Nordisk Inc., Plainsboro, NJ, USA.
FAU - Ji, X
AU  - Ji X
AD  - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
FAU - Kong, S X
AU  - Kong SX
AD  - Health Economics and Outcomes Research, Novo Nordisk Inc., Plainsboro, NJ, USA.
FAU - Milinovich, A
AU  - Milinovich A
AD  - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
FAU - Weng, W
AU  - Weng W
AD  - Health Economics and Outcomes Research, Novo Nordisk Inc., Plainsboro, NJ, USA.
FAU - Bauman, J M
AU  - Bauman JM
AD  - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
FAU - Ganguly, R
AU  - Ganguly R
AD  - Health Economics and Outcomes Research, Novo Nordisk Inc., Plainsboro, NJ, USA.
FAU - Burguera, B
AU  - Burguera B
AD  - Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
AD  - Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, OH, USA.
FAU - Kattan, M W
AU  - Kattan MW
AD  - Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
FAU - Zimmerman, R S
AU  - Zimmerman RS
AD  - Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
LA  - eng
GR  - Novo Nordisk, Inc.
PT  - Journal Article
DEP - 20190117
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/18 06:00
MHDA- 2019/01/18 06:00
CRDT- 2019/01/18 06:00
PHST- 2019/01/14 00:00 [accepted]
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2019/01/18 06:00 [medline]
PHST- 2019/01/18 06:00 [entrez]
AID - 10.1111/dme.13900 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 17. doi: 10.1111/dme.13900.

PMID- 30653704
OWN - NLM
STAT- Publisher
LR  - 20190218
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Jan 17
TI  - Effect of structured self-monitoring of blood glucose, with and without
      additional TeleCare support, on overall glycaemic control in non-insulin treated 
      Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial.
LID - 10.1111/dme.13899 [doi]
AB  - AIM: To examine the impact of structured self-monitoring of blood glucose, with
      or without TeleCare support, on glycaemic control in people with sub-optimally
      controlled Type 2 diabetes. METHODS: We conducted a 12-month, multicentre,
      randomized controlled trial in people with established (>1 year) Type 2 diabetes 
      not on insulin therapy, with sub-optimal glycaemic control [HbA1c >/=58 to </=119
      mmol/mol (>/=7.5% to </=13%)]. A total of 446 participants were randomized to a
      control group (n =151) receiving usual diabetes care, a group using structured
      self-monitoring of blood glucose alone (n =147) or a group using structured
      self-monitoring of blood glucose with additional monthly 'TeleCare' support (n
      =148). The primary outcome was HbA1c at 12 months. RESULTS: A total of 323
      participants (72%) completed the study; 116 (77%) in the control group, 99 (67%) 
      in the self-monitoring of blood glucose alone group and 108 (73%) in the
      self-monitoring of blood glucose plus TeleCare group. Compared to baseline, the
      mean HbA1c was lower in all groups at 12 months, with reductions of 3.3 mmol/mol 
      (95% CI -5.71 to -0.78) or 0.3% (95% CI -0.52 to -0.07; P=0.01) in the control
      group, 11.4 mmol/mol (95% CI -14.11 to -8.76) or 1.1% (-1.29 to -0.81; P<0.0001) 
      in the group using self-monitoring of blood glucose alone and 12.8 mmol/mol (95% 
      CI -15.34 to -10.31) or 1.2% (95% CI -1.40 to -0.94; P<0.0001) in the group using
      self-monitoring of blood glucose plus TeleCare. This represents a reduction in
      HbA1c of 8.9 mmol/mol (95% CI -11.97 to -5.84) or 0.8% (95% CI -1.10 to -0.54;
      P</=0.0001) with structured self-monitoring of blood glucose compared to the
      control group. Participants with lower baseline HbA1c , shorter duration of
      diabetes and higher educational achievement were more likely to achieve HbA1c
      </=53 mmol/mol (7.0%). CONCLUSIONS: Structured self-monitoring of blood glucose
      provides clinical and statistical improvements in glycaemic control in Type 2
      diabetes. No additional benefit, over and above the use of structured
      self-monitoring of blood glucose, was observed in glycaemic control with the
      addition of once-monthly TeleCare support. (Clinical trial registration no.:
      ISRCTN21390608).
CI  - (c) 2019 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on
      behalf of Diabetes UK.
FAU - Parsons, S N
AU  - Parsons SN
AUID- ORCID: https://orcid.org/0000-0002-5841-8309
AD  - Diabetes Research Group, Swansea University, Swansea.
FAU - Luzio, S D
AU  - Luzio SD
AUID- ORCID: https://orcid.org/0000-0002-7206-6530
AD  - Diabetes Research Group, Swansea University, Swansea.
FAU - Harvey, J N
AU  - Harvey JN
AD  - Diabetes Centre, Wrexham Maelor Hospital, Betsi Cadwaladr University Health
      Board, Bangor, UK.
FAU - Bain, S C
AU  - Bain SC
AUID- ORCID: https://orcid.org/0000-0001-8519-4964
AD  - Diabetes Research Group, Swansea University, Swansea.
FAU - Cheung, W Y
AU  - Cheung WY
AD  - Diabetes Research Group, Swansea University, Swansea.
FAU - Watkins, A
AU  - Watkins A
AUID- ORCID: https://orcid.org/0000-0003-3804-1943
AD  - Swansea Trials Unit, Swansea University, Swansea, UK.
FAU - Owens, D R
AU  - Owens DR
AUID- ORCID: https://orcid.org/0000-0003-1002-1238
AD  - Diabetes Research Group, Swansea University, Swansea.
LA  - eng
GR  - Roche Diabetes Care GmbH
GR  - European Foundation for the Study of Diabetes
GR  - LifeScan Programme
PT  - Journal Article
DEP - 20190117
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/01/18 06:00
MHDA- 2019/01/18 06:00
CRDT- 2019/01/18 06:00
PHST- 2019/01/14 00:00 [accepted]
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2019/01/18 06:00 [medline]
PHST- 2019/01/18 06:00 [entrez]
AID - 10.1111/dme.13899 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Jan 17. doi: 10.1111/dme.13899.

PMID- 30674623
OWN - NLM
STAT- Publisher
LR  - 20190124
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Jan 23
TI  - Genetic Determinants of Glycated Hemoglobin in Type 1 Diabetes.
LID - db180573 [pii]
LID - 10.2337/db18-0573 [doi]
AB  - Glycated hemoglobin (HbA1c) is an important measure of glycemia in diabetes.
      HbA1c is influenced by environmental and genetic factors, both in people with and
      without diabetes. We performed a genome-wide association study (GWAS) for HbA1c
      in a Finnish type 1 diabetes cohort, FinnDiane. Top results were examined for
      replication in type 1 diabetes cohorts DCCT/EDIC, WESDR, CACTI, EDC and RASS and 
      a meta-analysis was performed. Three SNPs in high LD on chromosome 13 near
      relaxin family peptide receptor 2 (RXFP2) were associated with HbA1c in FinnDiane
      at genome-wide significance (P<5x10(-8)). The minor alleles of rs2085277 and
      rs1360072 were associated with higher HbA1c also in the meta-analysis with RASS
      (P<5x10(-8)), where these variants had minor allele frequencies >/=1%.
      Furthermore, these SNPs were associated with HbA1c in a non-diabetic East Asian
      population (P</=0.013). A weighted genetic risk score created from 55 HbA1c
      associated variants from the literature was associated with HbA1c in FinnDiane
      but explained only a small amount of variation. Understanding the genetic basis
      of glycemic control and HbA1c may lead to better prevention of diabetic
      complications.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Syreeni, Anna
AU  - Syreeni A
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
FAU - Sandholm, Niina
AU  - Sandholm N
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
FAU - Cao, Jingjing
AU  - Cao J
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, M5G 0A4, Canada.
FAU - Toppila, Iiro
AU  - Toppila I
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
FAU - Maahs, David M
AU  - Maahs DM
AD  - Division of Endocrinology and Diabetes, Stanford Diabetes Research Center,
      Stanford University School of Medicine, Stanford, California, USA.
FAU - Rewers, Marian J
AU  - Rewers MJ
AD  - Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz
      Medical Campus, Aurora, Colorado, USA.
FAU - Snell-Bergeon, Janet K
AU  - Snell-Bergeon JK
AD  - Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz
      Medical Campus, Aurora, Colorado, USA.
FAU - Costacou, Tina
AU  - Costacou T
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Orchard, Trevor J
AU  - Orchard TJ
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, PA, USA.
FAU - Caramori, M Luiza
AU  - Caramori ML
AD  - Department of Medicine, Division of Endocrinology and Metabolism, University of
      Minnesota, Minneapolis, MN, USA.
FAU - Mauer, Michael
AU  - Mauer M
AD  - Department of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN, 
      USA.
FAU - Klein, Barbara E K
AU  - Klein BEK
AD  - Department of Ophthalmology and Visual Sciences, University of Wisconsin,
      Madison, WI, USA.
FAU - Klein, Ronald
AU  - Klein R
AD  - Department of Ophthalmology and Visual Sciences, University of Wisconsin,
      Madison, WI, USA.
FAU - Valo, Erkka
AU  - Valo E
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
FAU - Parkkonen, Maija
AU  - Parkkonen M
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
FAU - Forsblom, Carol
AU  - Forsblom C
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
FAU - Harjutsalo, Valma
AU  - Harjutsalo V
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Center, Biomedicum
      Helsinki, 00290, Helsinki, Finland.
AD  - Abdominal Center, Nephrology, University of Helsinki and Helsinki University
      Hospital, 00290, Helsinki, Finland.
AD  - Research Program for Clinical and Molecular Metabolism, Faculty of Medicine,
      University of Helsinki, 00290, Helsinki, Finland.
AD  - The Chronic Disease Prevention Unit, National Institute for Health and Welfare,
      00271, Helsinki, Finland.
FAU - Paterson, Andrew D
AU  - Paterson AD
AD  - Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, 
      ON, M5G 0A4, Canada.
CN  - DCCT/EDIC Research Group
FAU - Groop, Per-Henrik
AU  - Groop PH
CN  - FinnDiane Study Group
LA  - eng
PT  - Journal Article
DEP - 20190123
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/25 06:00
MHDA- 2019/01/25 06:00
CRDT- 2019/01/25 06:00
PHST- 2018/05/30 00:00 [received]
PHST- 2019/01/13 00:00 [accepted]
PHST- 2019/01/25 06:00 [entrez]
PHST- 2019/01/25 06:00 [pubmed]
PHST- 2019/01/25 06:00 [medline]
AID - db18-0573 [pii]
AID - 10.2337/db18-0573 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Jan 23. pii: db18-0573. doi: 10.2337/db18-0573.

PMID- 30665957
OWN - NLM
STAT- In-Data-Review
LR  - 20190202
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - Statement of Retraction. Francesco Oriente, Salvatore Iovino, Serena Cabaro,
      Angela Cassese, Elena Longobardi, Claudia Miele, Paola Ungaro, Pietro Formisano, 
      Francesco Blasi, and Francesco Beguinot. Prep1 Controls Insulin Glucoregulatory
      Function in Liver by Transcriptional Targeting of SHP1 Tyrosine Phosphatase.
      Diabetes 2011;60:138-147. DOI: 10.2337/db10-0860. PMID: 20864515.
PG  - 465-466
LID - 10.2337/db19-rt02c [doi]
CN  - American Diabetes Association
LA  - eng
PT  - Journal Article
PT  - Retraction of Publication
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
ROF - Diabetes. 2011 Jan;60(1):138-47. PMID: 20864515
PMC - PMC6341303
EDAT- 2019/01/23 06:00
MHDA- 2019/01/23 06:00
CRDT- 2019/01/23 06:00
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
AID - 68/2/465 [pii]
AID - 10.2337/db19-rt02c [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):465-466. doi: 10.2337/db19-rt02c.

PMID- 30665954
OWN - NLM
STAT- In-Data-Review
LR  - 20190122
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - Type 1 Diabetes in STAT Protein Family Mutations: Regulating the Th17/Treg
      Equilibrium and Beyond.
PG  - 258-265
LID - 10.2337/db18-0627 [doi]
AB  - Improvements in the immunological, molecular, and genetic technologies such as
      next-generation sequencing have led to an exponential increase in the number of
      monogenic immune dysregulatory syndromes diagnosed, where type 1 diabetes (T1D)
      forms part of the autoimmune manifestations. Here, we reviewed the mutations in
      the signal transducer and activator of transcription (STAT) protein family,
      namely gain-of-function (GOF) mutations in STAT1 and STAT3 as well as STAT5b
      deficiency, that show strong association to T1D susceptibility. The equilibrium
      of T-helper 17 (Th17) and regulatory T cells (Tregs) is often found altered in
      patients affected by STAT GOF mutations. While the increased number of Th17 cells
      and the concomitant decrease in Treg cells may explain T1D in STAT3 GOF patients,
      the reduced number of Th17 cells found in those carrying STAT1 GOF mutations
      added a new level of complexity on the exact role of Th17 in the pathogenesis of 
      T1D. Here, we describe the possible mechanisms through which STAT3 and STAT1 GOF 
      mutations may perturb the fate and function of Th17 and Tregs and explore how
      this may lead to the development of T1D. We propose that the study of monogenic
      diseases, and in particular STAT mutations, may not only improve our
      understanding of the function of the human immune system but also shed light onto
      the pathogenic mechanisms of T1D and the genetic variants that confer
      predisposition to the disease.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Fabbri, Marco
AU  - Fabbri M
AD  - Division of Immunology, Transplantation and Infectious Diseases, Diabetes
      Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
AD  - Vita-Salute San Raffaele University, Milan, Italy.
FAU - Frixou, Mikaela
AU  - Frixou M
AD  - School of Medicine, College of Medical, Veterinary and Life Sciences, University 
      of Glasgow, Glasgow, U.K.
FAU - Degano, Massimo
AU  - Degano M
AD  - Biocrystallography Unit, Division of Immunology, Transplantation and Infectious
      Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
FAU - Fousteri, Georgia
AU  - Fousteri G
AUID- ORCID: http://orcid.org/0000-0001-7745-7517
AD  - Division of Immunology, Transplantation and Infectious Diseases, Diabetes
      Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
      fousteri.georgia@hsr.it.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/23 06:00
MHDA- 2019/01/23 06:00
CRDT- 2019/01/23 06:00
PHST- 2018/06/12 00:00 [received]
PHST- 2018/11/11 00:00 [accepted]
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
AID - 68/2/258 [pii]
AID - 10.2337/db18-0627 [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):258-265. doi: 10.2337/db18-0627.

PMID- 30665953
OWN - NLM
STAT- In-Data-Review
LR  - 20190122
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
PG  - 248-257
LID - 10.2337/dbi18-0007 [doi]
AB  - Diabetic kidney disease (DKD) is now the principal cause of chronic kidney
      disease leading to end-stage kidney disease worldwide. As a primary contributor
      to the excess risk of all-cause and cardiovascular death in diabetes, DKD is a
      major contributor to the progressively expanding global burden of
      diabetes-associated morbidity and mortality. Sodium-glucose cotransporter 2
      (SGLT2) inhibitors are a newer class of antihyperglycemic agents that exert
      glucose-lowering effects via glycosuric actions. Preclinical studies and clinical
      trials of SGLT2 inhibitors have consistently demonstrated reduction of
      albuminuria and preservation of kidney function. In particular, SGLT2 inhibitors 
      lower risk of congestive heart failure, a major cardiovascular complication in
      DKD. This Perspective summarizes proposed mechanisms of action for SGLT2
      inhibitors, integrates these data with results of recent cardiovascular outcomes 
      trials, and discusses clinical applications for patients with DKD. The American
      Diabetes Association/European Association for the Study of Diabetes Consensus
      Report published online in October 2018 recommends SGLT inhibitors as preferred
      add-on therapy for patients with type 2 diabetes and established cardiovascular
      disease or chronic kidney disease, if kidney function is adequate. Results of the
      ongoing and just completed clinical trials conducted in patients with established
      DKD will facilitate further refinement of current guidelines.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Alicic, Radica Z
AU  - Alicic RZ
AUID- ORCID: http://orcid.org/0000-0002-5437-5700
AD  - Providence Health Care, Washington State University, Spokane, WA
      radica.alicic@providence.org.
AD  - University of Washington School of Medicine, Seattle, WA.
FAU - Neumiller, Joshua J
AU  - Neumiller JJ
AUID- ORCID: http://orcid.org/0000-0002-4734-7402
AD  - College of Pharmacy and Pharmaceutical Sciences, Washington State University,
      Spokane, WA.
FAU - Johnson, Emily J
AU  - Johnson EJ
AD  - Providence Health Care, Washington State University, Spokane, WA.
FAU - Dieter, Brad
AU  - Dieter B
AD  - Providence Health Care, Washington State University, Spokane, WA.
FAU - Tuttle, Katherine R
AU  - Tuttle KR
AD  - Providence Health Care, Washington State University, Spokane, WA.
AD  - University of Washington School of Medicine, Seattle, WA.
AD  - Kidney Research Institute, University of Washington, Seattle, WA.
AD  - Institute of Translational Health Sciences, University of Washington, Seattle,
      WA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/23 06:00
MHDA- 2019/01/23 06:00
CRDT- 2019/01/23 06:00
PHST- 2018/08/13 00:00 [received]
PHST- 2018/11/07 00:00 [accepted]
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
AID - 68/2/248 [pii]
AID - 10.2337/dbi18-0007 [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):248-257. doi: 10.2337/dbi18-0007.

PMID- 30665952
OWN - NLM
STAT- In-Data-Review
LR  - 20190202
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - Mitochondrial Stability in Diabetic Retinopathy: Lessons Learned From
      Epigenetics.
PG  - 241-247
LID - 10.2337/dbi18-0016 [doi]
AB  - Diabetic retinopathy remains the leading cause of acquired blindness in
      working-age adults. While the cutting-edge research in the field has identified
      many molecular, functional, and structural abnormalities, the exact molecular
      mechanism of this devastating disease remains obscure. Diabetic environment
      drives dysfunction of the power generator of the cell and disturbs the
      homeostasis of mitochondrial dynamic. Mitochondrial DNA (mtDNA) is damaged, the
      transcription of mtDNA-encoded genes is impaired, and the electron transport
      chain is compromised, fueling into a vicious cycle of free radicals. The
      hyperglycemic milieu also alters the epigenetic machinery, and mtDNA and other
      genes associated with mitochondrial homeostasis are epigenetically modified,
      further contributing to the mitochondrial damage. Thus, mitochondria appear to
      have a significant role in the development of diabetic retinopathy, and
      unraveling the mechanism responsible for their damage as well as the role of
      epigenetic modifications in mitochondrial homeostasis should identify novel
      therapeutic targets. This will have a major impact on inhibiting/halting diabetic
      retinopathy and preventing the loss of vision.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Kowluru, Renu A
AU  - Kowluru RA
AD  - Kresge Eye Institute, Wayne State University, Detroit, MI rkowluru@med.wayne.edu.
LA  - eng
GR  - R01 EY014370/EY/NEI NIH HHS/United States
GR  - R01 EY017313/EY/NEI NIH HHS/United States
GR  - R01 EY022230/EY/NEI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
PMC - PMC6341304
EDAT- 2019/01/23 06:00
MHDA- 2019/01/23 06:00
CRDT- 2019/01/23 06:00
PMCR- 2020/02/01 00:00
PHST- 2018/08/28 00:00 [received]
PHST- 2018/11/06 00:00 [accepted]
PHST- 2020/02/01 00:00 [pmc-release]
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
AID - 68/2/241 [pii]
AID - 10.2337/dbi18-0016 [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):241-247. doi: 10.2337/dbi18-0016.

PMID- 30665951
OWN - NLM
STAT- In-Data-Review
LR  - 20190122
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 68
IP  - 2
DP  - 2019 Feb
TI  - In This Issue of Diabetes.
PG  - 237-238
LID - 10.2337/db19-ti02 [doi]
LA  - eng
PT  - Editorial
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/01/23 06:00
MHDA- 2019/01/23 06:00
CRDT- 2019/01/23 06:00
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
AID - 68/2/237 [pii]
AID - 10.2337/db19-ti02 [doi]
PST - ppublish
SO  - Diabetes. 2019 Feb;68(2):237-238. doi: 10.2337/db19-ti02.